Medical experts in Sheffield have hailed as a "game changer" trials of a drug that could reduce the recurrence of bladder ...

Symptoms to look out for and when to see a doctor - There are roughly 10,000 people a year diagnosed with bladder cancer in ...

Adding durvalumab and bevacizumab to transarterial chemoembolization improved responses and progression-free survival.

The study found that patients with muscle-invasive bladder cancer had significantly less risk of cancer progressing or ...

Overall survival at two years was 82.2% in the durvalumab group and 75.2% in the comparator group. Durvalumab (brand name ...

Durvalumab did not improve outcomes compared with cetuximab in patients with head and neck squamous cell carcinoma who are ...

A lung cancer drug already available on the NHS has been proven to cut bladder cancer deaths and reduce the risk of the ...

The NRG-HN004 trial showed that durvalumab did not improve outcomes vs cetuximab in locoregionally advanced head and neck ...

A major clinical trial, led by the University of Sheffield, has revealed survival rates for patients with operable bladder ...

A 'game-changer' study found advanced bladder cancer patients treated with the drug durvalumab were a third less likely to ...

Durvalumab is under clinical development by AstraZeneca and currently in Phase II for Neuroendocrine Carcinoma.

The advent of immunotherapy based on immune checkpoint inhibitors has improved the treatment of advanced hepatocellular ...